Safety and Efficacy of HMG‐CoA Reductase Inhibitors for Treatment of Hyperlipidemia in Patients with HIV Infection
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Study Objective. To assess the efficacy and safety of HMG‐CoA reductase inhibitors (statins) in patients with human immunodeficiency virus (HIV) infection and hyperlipidemia. Design. Retrospective analysis. Setting. HIV clinic. Patients. Twenty‐six HIV‐infected patients with hyperlipidemia. Intervention. Five patients received pravastatin, 13 lovastatin, 10 simvastatin, and 2 atorvastatin (total 30 courses). Measurements and Main Results. Reductions in cholesterol and triglycerides were used to assess efficacy; creatine kinase (CK), liver enzymes, and myalgia were markers of statin toxicity. After a median of 8.2 and 7.2 months of treatment, the agents collectively reduced median baseline total cholesterol 27% (354 to 263 mg/dl) and triglycerides 15% (513 to 438 mg/dl), respectively. Two patients, one with marked CK elevations, experienced myalgias with lovastatin, and two experienced transaminase elevations 3 or more times the upper limit of normal. Conclusion. Statins are effective in reducing total cholesterol and triglycerides in HIV‐infected patients, although lipid levels infrequently return to normal. Lovastatin should be avoided in patients receiving concomitant drugs that may potentiate skeletal muscle toxicity with this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Cited by
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82
Drug–drug interactions that interfere with statin metabolism
Hirota, T., & Ieiri, I. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1056149 · Cited by 74
Metadata
- Authors
- Penzak, S. R., Chuck, S. K., & Stajich, G. V.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2000-09
- Volume
- 20
- Issue
- 9
- Pages
- 1066-1071
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2025341722
- Cited by
- 78
- References
- 1
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of HMG‐CoA Reductase Inhibitors for Treatment of Hyperlipidemia in Patients with HIV Infection. https://app.cochat.ai/papers/10.1592/phco.20.13.1066.35033
- The paper
- Penzak, S. R., Chuck, S. K., & Stajich, G. V. (2000). Safety and Efficacy of HMG‐CoA Reductase Inhibitors for Treatment of Hyperlipidemia in Patients with HIV Infection. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.20.13.1066.35033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.